O

Oscotec Inc
KOSDAQ:039200

Watchlist Manager
Oscotec Inc
KOSDAQ:039200
Watchlist
Price: 24 050 KRW -1.64% Market Closed
Market Cap: 919.8B KRW
Have any thoughts about
Oscotec Inc?
Write Note

Oscotec Inc
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Oscotec Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
O
Oscotec Inc
KOSDAQ:039200
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Biopharmaceuticals Co Ltd
KRX:326030
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Other Operating Expenses
-â‚©1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Other Operating Expenses
-â‚©2.7B
CAGR 3-Years
N/A
CAGR 5-Years
8%
CAGR 10-Years
N/A
No Stocks Found

Oscotec Inc
Glance View

Market Cap
913.8B KRW
Industry
Pharmaceuticals

Oscotec, Inc. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2007-01-17. The firm operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
15 998.74 KRW
Overvaluation 33%
Intrinsic Value
Price
O

See Also

Back to Top